본문 바로가기 주메뉴 바로가기
22대 대한민국 국회 국회정보길라잡이 국회의원검색
회원가입 로그인
HOME

정보검색

소장정보 검색

국회도서관 홈으로 정보검색 소장정보 검색
결과 내 검색 동의어 포함
결과 내 검색 동의어 포함

-

초록보기

Purpose Osimertinib is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for both EGFR-activating and T790M resistant mutation. The treatment efficacy of osimertinib was assessed in previously untreated patients with metastatic non–small cell lung carcinoma (NSCLC) harboring activating EGFR mutations in circulating tumor DNA (ctDNA) as well as tumor DNA.

Materials and Methods Patients with activating EGFR mutations in their tumor DNA underwent screening with ctDNA analysis using Mutyper and Cobas v2 assays. Enrolled subjects received osimertinib 80 mg, once daily. Primary endpoint was objective response rate (ORR) and secondary endpoints were ctDNA test sensitivity, progression-free survival (PFS), duration of response (DoR), and safety.

Results Among 39 screened patients, 29 were ctDNA positive for activating EGFR mutations and 19 were enrolled (ex19del, n=11; L858R/L861Q, n=7; G719A, n=1). Median age was 70 and most patients had brain metastases (15/19, 79%). ctDNA test sensitivity for activating EGFR mutations was 74% using both methods and 62% (Mutyper) or 64% (Cobas v2) for individual methods. ORR was 68% (13/19), median PFS was 11.1 months (95% confidence interval [CI], 0.0 to 26.7), and median DoR was 17.6 months (95% CI, 3.5 to 31.7). ORR and median PFS were significantly superior with ex19del (91%; 21.9 months; 95% CI, 5.5 to 38.3) than with L858R/L861Q (43%; 5.1 months; 95% CI, 2.3 to 7.9). One patient discontinued the drug because of drug-related interstitial pneumonitis.

Conclusion Osimertinib had favorable efficacy in the first-line treatment of metastatic NSCLC harboring activating EGFR mutations in ctDNA as well as tumor DNA.

권호기사

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 목차
(A) preoperative nomogram for predicting chemoresistance to neoadjuvant chemotherapy in patients with locally advanced cervical squamous carcinoma treated with radical hysterectomy Zhengjie Ou, Dan Zhao, Bin Li, Yating Wang, Shuanghuan Liu, Yanan Zhang p. 233-242

Association of insulin, metformin, and statin with mortality in breast cancer patients Mihong Choi, Jiyeon Han, Bo Ram Yang, Myoung-jin Jang, Miso Kim, Dae-Won Lee, Tae-Yong Kim, Seock-Ah Im, Han-Byoel Lee, Hyeong-Gon Moon, Wonshik Han, Dong-Young Noh, Kyung-Hun Lee p. 65-76

Impact of awareness of breast density on perceived risk, worry, and intentions for future breast cancer screening among Korean women Anh Thi Ngoc Tran, Ji Hae Hwang, Eunji Choi, Yun Yeong Lee, Mina Suh, Chan Wha Lee, Yeol Kim, Kui Son Choi p. 55-64

Development of a tongue immobilization device using a 3D printer for intensity modulated radiation therapy of nasopharyngeal cancer patients Sang Gyu Ju, Yong Chan Ahn, Yeong-bi Kim, Seung Gyu Park, Yoo-mi Choi, Cho Hee Na, Chae-Seon Hong, Dongryul Oh, Dong Yeol Kwon, Cheol Chong Kim, Dong Hyeon Kim p. 45-54

(The) broad variability in dental age observed among childhood survivors is cancer specific Patrycja Proc, Joanna Szczepanska, Malgorzata Zubowska, Beata Zalewska-Szewczyk, Wojciech Mlynarski p. 252-260

Impact of the learning curve on the survival of abdominal or minimally invasive radical hysterectomy for early-stage cervical cancer Lan Ying Li, Lan Ying Wen, Sun Hee Park, Eun Ji Nam, Jung Yun Lee, Sunghoon Kim, Young Tae Kim, Sang Wun Kim p. 243-251

Adherence to cancer prevention guidelines and endometrial cancer risk : evidence from a systematic review and dose-response meta-analysis of prospective studies Hui Sun, Qing Chang, Ya-Shu Liu, Yu-Ting Jiang, Ting-Ting Gong, Xiao-Xin Ma, Yu-Hong Zhao, Qi-Jun Wu p. 223-232

Cervical cancer screening rate and willingness among female migrants in Shenzhen, China : three-year changes in citywide surveys Wei Lin, Bin Chen, Bo Wu, Shixin Yuan, Chuyan Zhong, Weikang Huang, Haiyan Hu, Zhihua Liu, Yueyun Wang p. 212-222

Uptake of family-specific mutation genetic testing among relatives of patients with ovarian cancer with BRCA1 or BRCA2 mutation Go Woon Jeong, Wonkyo Shin, Dong Ock Lee, Sang-Soo Seo, Sokbom Kang, Sang-Yoon Park, Myong Cheol Lim p. 207-211

Prognostic value of serum soluble programmed death-ligand 1 and dynamics during chemotherapy in advanced gastric cancer patients Woochan Park, Ju-Hee Bang, Ah-Rong Nam, Mei Hua Jin, Hyerim Seo, Jae-Min Kim, Kyoung Seok Oh, Tae-Yong Kim, Do-Youn Oh p. 199-206

Long non-coding RNA CASC15 promotes intrahepatic cholangiocarcinoma possibly through inducing PRDX2/PI3K/AKT axis Yuan Zhang, Lufei Zhang, Sinan Lu, Yucheng Xiang, Cheng Zeng, Tianyu He, Yuan Ding, Weilin Wang p. 184-198

Prediction of pathologic response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma incorporating hematological biomarkers Yingjia Wu, Jinbin Chen, Lei Zhao, Qiaoqiao Li, Jinhan Zhu, Hong Yang, Suping Guo, Mian Xi p. 172-183

Spatial distribution and prognostic implications of tumor-infiltrating FoxP3– CD4+ T cells in biliary tract cancer Hyung-Don Kim, Jwa Hoon Kim, Yeon-Mi Ryu, Danbee Kim, Sunmin Lee, Jaehoon Shin, Seung-Mo Hong, Ki-Hun Kim, Dong-Hwan Jung, Gi Won Song ... [et al.] p. 162-171

(An) innovative prognostic model based on four genes in Asian patient with gastric cancer Jiahui Chen, Anqiang Wang, Jun Ji, Kai Zhou, Zhaode Bu, Guoqing Lyu, Jiafu Ji p. 148-161

Adherence to the recommended intake of calcium and colorectal cancer risk in the HEXA study Jeeyoo Lee, Aesun Shin, Ji-Yeob Choi, Daehee Kang, Jong-Koo Lee p. 140-147

Systemic inflammatory biomarkers, especially fibrinogen to albumin ratio, predict prognosis in patients with pancreatic cancer Lin Fang, Fei-Hu Yan, Chao Liu, Jing Chen, Dan Wang, Chun-Hui Zhang, Chang-Jie Lou, Jie Lian, Yang Yao, Bo-Jun Wang ... [et al.] p. 131-139

Clinical application of targeted deep sequencing in metastatic colorectal cancer patients : actionable genomic alteration in K-MASTER project Youngwoo Lee, Soohyeon Lee, Jae Sook Sung, Hee-Joon Chung, Ah-reum Lim, Ju Won Kim, Yoon Ji Choi, Kyong Hwa Park, Yeul Hong Kim p. 123-130

Evaluation and comparison of predictive value of tumor regression grades according to Mandard and Becker in locally advanced gastric adenocarcinoma Yilin Tong, Yanmei Zhu, Yan Zhao, Zexing Shan, Dong Liu, Jianjun Zhang p. 112-122

Active treatment improves overall survival in extremely older non-small cell lung cancer patients : a multicenter retrospective cohort study Su Yeon Lee, Yoon-Ki Hong, Wonjun Ji, Jae Cheol Lee, Chang Min Choi, Korean Association for Lung Cancer, Korea Central Cancer Registry p. 104-111

(A) phase Ⅱ trial of osimertinib as the first-line treatment of non–small cell lung cancer harboring activating EGFR mutations in circulating tumor DNA : LiquidLung-O-cohort 1 Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim p. 93-103

Phase Ⅱ study of pemetrexed as a salvage chemotherapy for thymidylate synthase-low squamous cell lung cancer Mihong Choi, Heung Tae Kim, Ji-Youn Han, Geon Kook Lee, Soo-Hyun Lee, Kun Young Lim, Jungnam Joo, Hye Jin Won, Jin Soo Lee, Youngjoo Lee p. 87-92

(Correspondence) Green tea consumption and stomach cancer risk in women : a meta-analysis of population-based cohort studies Jong-Myon Bae p. 289-290

Hyperammonemic encephalopathy mimicking ornithine transcarbamylase deficiency in fibrolamellar hepatocellular carcinomas : successful treatment with continuous venovenous hemofiltration and ammonia scavengers Jeong-Seon Lee, Hye Young Jin, Jung Min Ko, Seoung Hoon Kim, Nayoung Han, Byung Kiu Park, Meerim Park, Hyeon Jin Park, Jun Ah Lee p. 283-288

Sequential treatment with an immune checkpoint inhibitor followed by a small-molecule targeted agent increases drug-induced pneumonitis Jongheon Jung, Hyae Young Kim, Dong-Gil Kim, Seog Yun Park, A Ra Ko, Ji-Youn Han, Heung Tae Kim, Jin Soo Lee, Youngjoo Lee p. 77-86

Chondroblastoma's lung metastases treated with denosumab in pediatric patient Marco Focaccia, Marco Gambarotti, Rossella Hakim, Anna Paioli, Marilena Cesari, Benedetta Spazzoli, Paolo Spinnato, Davide Donati, Michele Rocca, Alessandra Longhi p. 279-282

Prognostic impact of age at the time of diagnosis in Korean patients with diffuse large B-cell lymphoma in the rituximab era : a single institution study Hee Sang Hwang, Meejeong Kim, Chan-Sik Park, Dok Hyun Yoon, Cheolwon Suh, Jooryung Huh, Heounjeong Go p. 270-278

Effectiveness and safety of dabrafenib in the treatment of 20 Chinese children with BRAF[V600E]-mutated Langerhans cell histiocytosis Ying Yang, Dong Wang, Lei Cui, Hong-Hao Ma, Li Zhang, Hong-Yun Lian, Qing Zhang, Xiao-Xi Zhao, Li-Ping Zhang, Yun-Ze Zhao, Na Li, Tian-You Wang, Zhi-Gang Li, Rui Zhang p. 261-269

Cancer incidence and survival among adolescents and young adults in Korea : an update for 2016 Meerim Park, Jiwon Lim, Jun Ah Lee, Byung Kiu Park, Kyu-Won Jung, Young-Joo Won, Hyeon Jin Park p. 32-44

Pilot study for the psychometric validation of the Sheffield Profile for Assessment and Referral to Care (SPARC) in Korean cancer patients Jung Hye Kwon, Sun Kyung Baek, Do Yeun Kim, Yu Jung Kim, Myung Ah Lee, Hye Jin Choi, Ja Min Byun, Jin Young Jeong, Sam H Ahmedzai, Geun-Doo Jang p. 25-31

TM4SF4 and LRRK2 are potential therapeutic targets in lung and breast cancers through outlier analysis Kyungsoo Jung, Joon-Seok Choi, Beom-Mo Koo, Yu Jin Kim, Ji-Young Song, Minjung Sung, Eun Sol Chang, Ka-Won Noh, Sungbin An, Mi-Sook Lee ... [et al.] p. 9-24

Practical advice for South Korean medical researchers regarding open-access and predatory journals Chai Hong Rim p. 1-8

참고문헌 (27건) : 자료제공( 네이버학술정보 )

참고문헌 목록에 대한 테이블로 번호, 참고문헌, 국회도서관 소장유무로 구성되어 있습니다.
번호 참고문헌 국회도서관 소장유무
1 Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046-61. 미소장
2 Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689-99. 미소장
3 Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35:1288-96. 미소장
4 Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629-40. 미소장
5 Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFRmutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113-25. 미소장
6 Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, et al. Osimertinib as first-line treatment of EGFR mutationpositive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:841-9. 미소장
7 Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41-50. 미소장
8 Cho BC, Chewaskulyong B, Lee KH, Dechaphunkul A, Sriuranpong V, Imamura F, et al. Osimertinib versus standard of care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian Subset. J Thorac Oncol. 2019;14:99-106. 미소장
9 Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, et al. Preclinical comparison of osimertinib with other EGFRTKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22:5130-40. 미소장
10 Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced nonsmall-cell lung cancer. J Clin Oncol. 2018;36:3290-7. 미소장
11 Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014;9:1345-53. 미소장
12 Qiu M, Wang J, Xu Y, Ding X, Li M, Jiang F, et al. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2015;24:206-12. 미소장
13 Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, Brown H, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 2015;90:509-15. 미소장
14 Park CK, Cho HJ, Choi YD, Oh IJ, Kim YC. A phase II trial of osimertinib in the second-line treatment of non-small cell lung cancer with the EGFR T790M mutation, detected from circulating tumor DNA: LiquidLung-O-Cohort 2. Cancer Res Treat. 2019;51:777-87. 미소장
15 Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. 2016;34:3375-82. 미소장
16 Gray JE, Okamoto I, Sriuranpong V, Vansteenkiste J, Imamura F, Lee JS, et al. Tissue and plasma EGFR mutation analysis in the FLAURA trial: osimertinib versus comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer. Clin Cancer Res. 2019;25:6644-52. 미소장
17 Molina-Vila MA, Stahel RA, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzon-Ibanez M, et al. Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial. J Thorac Oncol. 2020;15:416-25. 미소장
18 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47. 미소장
19 Weber B, Meldgaard P, Hager H, Wu L, Wei W, Tsai J, et al. Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer. 2014;14:294. 미소장
20 Jenkins S, Yang JC, Ramalingam SS, Yu K, Patel S, Weston S, et al. Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2017;12:1061-70. 미소장
21 Choi CM, Kim HC, Jung CY, Cho DG, Jeon JH, Lee JE, et al. Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014. Cancer Res Treat. 2019;51:1400-10. 미소장
22 Sacher AG, Komatsubara KM, Oxnard GR. Application of plasma genotyping technologies in non-small cell lung cancer: a practical review. J Thorac Oncol. 2017;12:1344-56. 미소장
23 Bhatt VR, D’Souza SP, Smith LM, Cushman-Vokoun AM, Noronha V, Verma V, et al. Epidermal growth factor receptor mutational status and brain metastases in non-small-cell lung cancer. J Glob Oncol. 2017;3:208-17. 미소장
24 Sheng M, Wang F, Zhao Y, Li S, Wang X, Shou T, et al. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis. Eur J Clin Pharmacol. 2016;72:1-11. 미소장
25 Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16:141-51. 미소장
26 Hong MH, Kim HR, Ahn BC, Heo SJ, Kim JH, Cho BC. Realworld analysis of the efficacy of rebiopsy and EGFR mutation test of tissue and plasma samples in drug-resistant non-small cell lung cancer. Yonsei Med J. 2019;60:525-34. 미소장
27 Zhou C, Imamura F, Cheng Y, Okamoto I, Cho BC, Lin MC, et al. Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial. J Clin Oncol. 2019;37(15 Suppl):9020. 미소장

추천서가 (다양한 추천 자료를 만나보세요)

권호기사보기

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 기사목차